Nanosafer Sample Clauses

Nanosafer. Nanosafer10 was developed by the National Research Centre for the Working Environment (NRCWE) and the Danish Technological Institute (DTI) in Denmark, in collaboration with the Danish Industry, the Branch Organization for Industry Workers, and the Ministry for Science and Education (Kristensen et al., 2010). The tool provides a risk evaluation in the near and far-field for short (15 minutes) and long-term (8-hours) exposure for occupational exposures involving potential inhalation of MN as respirable dust, i.e. handling powders, releases from grinding which release dust with a known or assumed fraction of NM (NOAA) in the airborne fraction and in case of spills. In contrast to ART, the Nanosafer considers the near field to be the space around the source, rather than the worker (which means that a worker can be either in the near-field or the far-field). The tool estimates whether the material is nano-relevant from the input parameters (i.e. particles ≤ 200 nm and/or products with a specific surface area (SA) ≥ 30 m2 g-1). The emission rate for a process is determined within the tool, based on either dustiness data (Eo) adjusted for the activity energy (hi) and applied mass-flow (dM/dt) or a constant release rate (Ei,o). A first- order quantitative two-box aerosol dispersion model, as with most of the higher tier models, is then used to determine the near-field (NF) and far-field (FF) concentrations. In addition to the dust transport between the two compartments, the aerosol decay rates are in principle considered as function of the ventilation rates, efficiencies of exposure control, ingression of particles from other sources, coagulation, and aerosol surface deposition by diffusion and sedimentation (Xxxxxxxxx et al., 2011). In the simplified Nanosafer model, only the calibrated aerosol transport and decay rates from the NF to the (FF (NFNF-FF) and from the FF to the NF (Xxxxxxx, 1999) are considered in the assessment as well as the residual concentration in the NF and FF. NF = ⎡ QNF ⋅ CFF ⎤ ⋅ [Q ⋅ Δt + e(−QNF ⋅Δt ) −1] FF → NF ⎢Δt ⋅ (Q )2 ⎥ NF ⎣ NF ⎦ NF = ⎡QNF ⋅ CNF ⋅ (Ei ⋅ Δt )⎤ ⋅ [Q ⋅ Δt + e(−QNF ⋅Δt ) −1] NF →FF ⎢ ⎣ Δt ⋅ (QNF ) ⎥ NF ⎦ ⎡ (C + C )⎤ NFresidual = ⎢0.5 ⋅ ⎣ NF ,t−1 (QNF NF ,t ⋅ dt) ⎥ ⋅ [1 − e(−QNF ⋅dt ) ] ⎦ ⎡ (C + C )⎤ FFresidual = ⎢0.5 ⋅ ⎣ FF ,t −1 (QFF FF ,t ⋅ dt ) ⎥ ⋅ [1 − e(−QFF ⋅dt ) ] ⎦ The output from Nanosafer is an integrated risk assessment for short-term (15 min) and 8-hour NF and FF exposure. The risk scaling is based on compila...
AutoNDA by SimpleDocs

Related to Nanosafer

  • Rhytidectomy Scar revision, regardless of symptoms. • Sclerotherapy for spider veins. • Skin tag removal. • Subcutaneous injection of filling material. • Suction assisted Lipectomy. • Tattooing or tattoo removal except tattooing of the nipple/areola related to a mastectomy. • Treatment of vitiligo. • Standby services of an assistant surgeon or anesthesiologist. • Orthodontic services related to orthognathic surgery. • Cosmetic procedures when performed primarily: o to refine or reshape body structures or dental structures that are not functionally impaired; o to improve appearance or self-esteem; or o for other psychological, psychiatric or emotional reasons. • Drugs, biological products, hospital charges, pathology, radiology fees and charges for surgeons, assistant surgeons, attending physicians and any other incidental services, which are related to cosmetic surgery.

  • Biological Samples If so specified in the Protocol, Institution and Principal Investigator may collect and provide to Sponsor or its designee Biological Samples (“Biological Samples”). 12.2.

  • Nepotism No employee shall be awarded a position where he/she is to be directly supervised by a member of his/her immediate family. “

  • FABRICATION Making up data or results and recording or reporting them.

  • Influenza Vaccine Upon recommendation of the Medical Officer of Health, all employees shall be required, on an annual basis to be vaccinated and or to take antiviral medication for influenza. If the costs of such medication are not covered by some other sources, the Employer will pay the cost for such medication. If the employee fails to take the required medication, she may be placed on an unpaid leave of absence during any influenza outbreak in the home until such time as the employee has been cleared by the public health or the Employer to return to the work environment. The only exception to this would be employees for whom taking the medication will result in the employee being physically ill to the extent that she cannot attend work. Upon written direction from the employee’s physician of such medical condition in consultation with the Employer’s physician, (if requested), the employee will be permitted to access their sick bank, if any, during any outbreak period. If there is a dispute between the physicians, the employee will be placed on unpaid leave. If the employee gets sick as a reaction to the drug and applies for WSIB the Employer will not oppose the application. If an employee is pregnant and her physician believes the pregnancy could be in jeopardy as a result of the influenza inoculation and/or the antiviral medication she shall be eligible for sick leave in circumstances where she is not allowed to attend at work as a result of an outbreak. This clause shall be interpreted in a manner consistent with the Ontario Human Rights Code.

  • Influenza Vaccination The parties agree that influenza vaccinations may be beneficial for patients and employees. Upon a recommendation pertaining to a facility or a specifically designated area(s) thereof from the Medical Officer of Health or in compliance with applicable provincial legislation, the following rules will apply:

  • Manufacturing (a) The Supplier shall without limitation be responsible, at no additional cost to the Purchaser, for: sourcing and procuring all raw materials for the Products; obtaining all necessary approvals, permits and licenses for the manufacturing of the Products; providing sufficient qualified staff and workers to perform the obligations under this Purchase Agreement; implementing and maintaining effective inventory and production control procedures with respect to the Products; and handling other matters as reasonably requested by the Purchaser from time to time.

  • Human Leukocyte Antigen Testing This plan covers human leukocyte antigen testing for A, B, and DR antigens once per member per lifetime to establish a member’s bone marrow transplantation donor suitability in accordance with R.I. General Law §27-20-36. The testing must be performed in a facility that is: • accredited by the American Association of Blood Banks or its successors; and • licensed under the Clinical Laboratory Improvement Act as it may be amended from time to time. At the time of testing, the person being tested must complete and sign an informed consent form that also authorizes the results of the test to be used for participation in the National Marrow Donor program.

  • PIONEERING Pioneering may not extend past construction that will be completed during the current construction season. Pioneering may not extend more than 500 feet beyond completed construction unless approved in writing by the Contract Administrator. In addition, the following actions must be taken as pioneering progresses:  Drainage must be provided on all uncompleted construction.  Road pioneering operations may not undercut the final cut slope or restrict drainage.  Culverts at live stream crossings must be installed during pioneering operations prior to embankment.

  • Manufacture 2.1. The LED(s) on the LED module shall be equipped with suitable fixation elements.

Time is Money Join Law Insider Premium to draft better contracts faster.